2[1]Mikhalovsky SV. emerging technologies in extracorporeal treatment:focus on adsorption. Perfusion, 2003,18(7) :47 - 54
3[2]Vanholder R. Review on uremic toxins: Classification, concentration,and interindividual variability. Kidney International,2003,63(5): 1934- 1943
4[3]James F. Removal of Middle Molecules with Sorbents. Artif Cells Blood Substit Immobil Biotechnol, 2002,30(5- 6):547- 554
5[4]Clark WR. Middle molecules and small- molecular- weight protiens in ESRD: Properties and strategies for their removal. Adv Ren Replace Ther,2003, 10(4) :270 - 278
6[5]Morena MD. Effect of novel adsorbent on cytokine responsiveness to uremic plasma. Kidney Int,2003,63(3):1150-4
7[6]Winchester JF. The next step from high - flux dialysis: application of sorbent technology. Blood Purif, 2002,20(1):81-6
8[7]Vanholder R. Survival of hemodialysis patients uremic toxin removal.Artifi Organ,2003,27 (7) :218 - 23
9[9]Schlaeper C. High clearance continuious renal replacement therapy with a modified dialysis machine. Kidney Int Suppl, 1999,72(56): S20 - 3
10[10]Lesaffer G. Comparative kinetics of the uremic toxin p - cresol versus creatinine in rats with and without renal failure. Kidney Int, 2003, 64(4): 1365 - 73
2Chang YS, Liu C J, Wu TH, et al. Survival analysis in systemic lupus erythematosus patients on maintenance dialysis: a nationwide population - based study in Taiwan [ J] . Rheumatology (Oxford) , 2013, 52 (1) : 166 - 172.
3Beladi - Mousavi SS, Alemzadeh - Ansari M J, Alemzadeh - Ansari MH, et al. Long - term survival of patients with end - stage renal disease on maintenance hemodialysis: a multicenter study in Iran [ J] . Iran J Kidney Dis, 2012, 6 (6): 452-456.
4Farin, Rashid-Farokhi Guitti, Pourdowlat Mohammad-Reza, et al. Uremic pleuritis in chronic hemodialysis patients.Hemodialysis international. International Symposium on Home Hemodialysis, 2013, 17(1):94-100.
